Fingerprints for inflammatory subtypes in asthma - Inflammatory subtypes in asthma

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•* Age >18 years
•* Clinical presentation of asthma
•* Airway hyperresponsiveness, indicated by a positive methacholine challenge with PC20 * 8 mg/ml OR
•* reversibility in FEV1 of * 12% predicted
•* Requiring inhaled corticosteroids at high doses (* 500 ug ICS fluticasone or equivalent)
•* Non-smoking or stopped smoking more than 12 months ago and 10 pack years or less
•* No condition or treatment which may increase the risk of bleeding
•* No other clinically significant abnormality on history and clinical examination
•* Able to give written and dated informed consent prior to any study-specific procedures
•- sputum eosinophils > 3% * eosinophilic asthma
•- sputum eosinophils < 1% * non-eosinophilic asthma

•* Change in the dose of ICS in 4 weeks prior to screening
•* A course of oral corticosteroids, antibiotics or a respiratory infection within 4 weeks prior to the study
•* Use of anti-leukotrienes, chromoglycates, anti-cholinergics within 4 weeks prior to the study
•* Pregnancy
•* Concomitant disease or condition which could interfere with the conduct of the study, or which treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study
•* Unwillingness or inability to comply with the study protocol for any other reason

发起方